1. Endovascular Live Case Mount Sinai Hospital, NY
11/22/2017

2. History and Examination
58 year old, male
HTN, smoking
Severe bilateral lower extremity claudication (Rutherford category 3)
ABI: Right (0.68), Left (0.73)
BP- 136/78 mmHg, Pulse- 64/min

3. Labs and non-invasive testing
Hb- 13.0
Platelets – 207 k
INR – 1.3
Creatinine – 0.9

4. Inflow

5. Left leg run off

6. Strategy Right and left CFA access (7F, 25 cm sheath) Lesion crossing
Predilatation
Stenting (SE, BE, Covered stents)

7. Iliac Occlusive Disease
Epidemiology
Peripheral Arterial Disease (PAD) affects approximately 10% of U.S. adults above the age of 60 years1
Untreated PAD may progress from pain to tissue loss, and eventually to amputation.
Approximately 1/3 of PAD involves the iliac arteries2
Treatment
Stenting is effective as primary therapy for iliac artery stenoses and occlusions (ACCF / AHA practice guidelines)3
Criqui MH, Aboyans V. Epidemiology of peripheral artery disease. Circulation Research 2015;116(9):
Kumar V. Defining the role of covered stents in aorto-iliac interventions. Interventional Cardiology 2013;5(1):45-52.
Anderson JL, Halperin JL, Albert NM, et al. Management of patients with peripheral artery disease (compilation of 2005 and 2011 ACCF/AHA guideline recommendations): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013;127(13):
Products listed may not be available in all markets.
GORE®, VBX, VIABAHN®, and designs are trademarks of W. L. & Gore Associates. CBAS is a trademark of Carmeda AB, a wholly owned subsidiary of W.L. Gore & Associates, Inc. © 2017 W. L. & Gore Associates, Inc.

8. Treatment guidelines for IOD based on lesion complexity – 2007
Products listed may not be available in all markets.
GORE®, VBX, VIABAHN®, and designs are trademarks of W. L. & Gore Associates. CBAS is a trademark of Carmeda AB, a wholly owned subsidiary of W.L. Gore & Associates, Inc. © 2017 W. L. & Gore Associates, Inc.